Bonerge Lifesience is excited to announce the launch of its new branded ingredient, GlucoSober, designed to support blood sugar and lipid metabolism as well as weight management. As Berberine and its so-called "natural Ozempic" gain viral popularity on TikTok, many supplement brands incorporate Berberine into their products. To meet the increasing demand for higher quality products, Bonerge introduces GlucoSober, a superior Dihydroberberine ingredient, offering a new option for supplement brands.

Dihydroberberine, GlucoSober’s active component, is a Berberine derivative with similar benefits. Importantly, Dihydroberberine has better bioavailability than Berberine. Unlike Berberine, which has been reported to cause side effects such as vomiting, Dihydroberberine has no report of adverse effects in published toxicology studies.

Berberine's surge in popularity is due to its weight loss mechanism similar to Semaglutide's. As both of them can boost the secretion of GLP-1.¹ GLP-1 increases satiety, reduces food intake, enhances energy expenditure, and delays gastric emptying time.² Besides its weight loss effects, research indicates that Berberine can improve insulin sensitivity3, reduce blood sugar levels⁴, and enhance lipid metabolism by promoting the conversion of white fat to brown fat and lowering plasma LDL cholesterol, free fatty acids, and total cholesterol levels. ^4-5

Through extensive research and development, GlucoSober is produced with a unique manufacturing procedure that yields high-quality crystalline Dihydroberberine. Even the granulated specifications, can maintain a high assay level compared to other Dihydroberberine on the market while maintaining the flowability of powder. This allows for maximizing the efficacy of Dihydroberberine and providing brands with more versatile product applications.

To further explore the potential and possible applications of GlucoSober, Bonerge plans to conduct self-GRAS certification, efficacy studies, and human trials. For more information, please contact Bonerge.

Reference

[1] Araj-Khodaei, Mostafa et al. “Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review.”

[2] Baggio, Laurie L, and Daniel J Drucker. “Biology of incretins: GLP-1 and GIP.”

[3] Kong, Wei-Jia et al. “Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression.”

[4] Mi, Jia et al. “Effect of berberine on the HPA-axis pathway and skeletal muscle GLUT4 in type 2 diabetes mellitus rats.”

[5] Hu, Xiaofei et al. “Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation.”

Disclaimer *
The information available on this site is solely for the purpose of providing general knowledge. All information, including any text, expression or statement, is intended for business-to-business customers only and not intended for end-use consumers.